Virtual Library
Start Your Search
K. So-Mye
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-008 - Combination of Bavacizumab with Conventional Chemotherapy Shows Better Prognosis in Patients with Lung Cancer with Liver Metastasis (ID 7965)
09:00 - 09:00 | Author(s): K. So-Mye
- Abstract
Background:
Lung cancer is one of the worst prognostic cancers. The survival rate of patients with stage 4 lung cancer is low, especially when invading major organs such as the liver and adrenal glands. Bevacizumab, anti-angiogenesis monoclonal antibody, showed better prognosis combination with conventional chemotherapy of lung adenocarcinoma. We compared progression of liver metastasis and overall survival, the patients who had lung cancer with liver metastasis, conventional chemotherapy or target agents and adding bevacizumab to conventional chemotherapy.
Method:
From 2010 to 2016, we analyzed the differences in treatment outcome between classic chemotherapy or target agents and adding bevacuzimab with conventional chemotherapy among patients with hepatic metastasis in lung cancer patient. Compare the overall survival, response to liver metastasis, and progression of liver metastasis.
Result:
There are 10 patients with conventional chemotherapy or target agents and 5 patients with adding bevacizumab to conventional chemotherapy. Both of them are male predominance, more elderly at adding bevacizumab group. The time taken to worsen the hepatic metastasis was 77.7 days in conventional chemotherapy or target agents group and 174 days in the group with bevacizumab. Overall survival was 134 days in the chemotherapy or target agents group and 332 days in the bevacizumab combination group.
Conclusion:
In lung cancer patients with hepatic metastasis, the efficacy of inhibition of hepatic metastasis was better in patients with combined angiogenesis inhibitor therapy than cytotoxic chemotherapy. We suggest that individual metastatic organ, as like liver, which has poor prognosis, has to reevaluate response to therapy, because of tumor microenvironment.
